Literature DB >> 17179359

Transient hepatic intensity differences: part 2, Those not associated with focal lesions.

Stefano Colagrande1, Nicoletta Centi, Roberta Galdiero, Alfonso Ragozzino.   

Abstract

OBJECTIVE: The purpose of our study was to evaluate and to show the range of appearance of transient hepatic signal intensity differences when not associated with focal lesions, and to correlate morphology, cause, and pathogenesis.
CONCLUSION: Hepatic arterial phenomena, visualized on MRI and CT, must be considered important signs of underlying liver disorders, which these phenomena contribute to evaluate. Accordingly, the hepatic arterial phase must always be performed on MRI as well as on CT, even if no focal lesion is expected.

Entities:  

Mesh:

Year:  2007        PMID: 17179359     DOI: 10.2214/AJR.05.1367

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  13 in total

1.  Acute portal vein thrombosis: an important mimic of malignancy on FDG PET/CT.

Authors:  Gordon W Cowell; Laura K Thomson; Michael Digby; Fat Wui Poon
Journal:  BMJ Case Rep       Date:  2011-10-04

2.  Giant area of transient hepatic attenuation difference, mimicking incidentaloma at liver ultrasound.

Authors:  Gaspare Parrinello; Daniele Torres; Giuseppe Licata
Journal:  Intern Emerg Med       Date:  2010-06-30       Impact factor: 3.397

3.  Hepatic abnormal perfusion visible by magnetic resonance imaging in acute pancreatitis.

Authors:  Wei Tang; Xiao-Ming Zhang; Zhao-Hua Zhai; Nan-Lin Zeng
Journal:  World J Radiol       Date:  2013-12-28

Review 4.  Liver Masses: What Physicians Need to Know About Ordering and Interpreting Liver Imaging.

Authors:  Arman Sheybani; Ron C Gaba; R Peter Lokken; Senta M Berggruen; Winnie A Mar
Journal:  Curr Gastroenterol Rep       Date:  2017-10-18

5.  Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.

Authors:  Gamal Shiha; Alaa Ibrahim; Ahmed Helmy; Shiv Kumar Sarin; Masao Omata; Ashish Kumar; David Bernstien; Hitushi Maruyama; Vivek Saraswat; Yogesh Chawla; Saeed Hamid; Zaigham Abbas; Pierre Bedossa; Puja Sakhuja; Mamun Elmahatab; Seng Gee Lim; Laurentius Lesmana; Jose Sollano; Ji-Dong Jia; Bahaa Abbas; Ashraf Omar; Barjesh Sharma; Diana Payawal; Ahmed Abdallah; Abdelhamid Serwah; Abdelkhalek Hamed; Aly Elsayed; Amany AbdelMaqsod; Tarek Hassanein; Ahmed Ihab; Hamsik GHaziuan; Nizar Zein; Manoj Kumar
Journal:  Hepatol Int       Date:  2016-10-06       Impact factor: 6.047

Review 6.  Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions.

Authors:  Matteo Renzulli; Nicolò Brandi; Giulia Argalia; Stefano Brocchi; Andrea Farolfi; Stefano Fanti; Rita Golfieri
Journal:  Radiol Med       Date:  2022-01-13       Impact factor: 3.469

7.  Parenchymal signal intensity in 3-T body MRI of dogs with hematopoietic neoplasia.

Authors:  Daniel A Feeney; Leslie C Sharkey; Susan M Steward; Katherine L Bahr; Michael S Henson; Daisuke Ito; Timothy D O'Brien; Carl R Jessen; Brian D Husbands; Antonella Borgatti; Jaime F Modiano
Journal:  Comp Med       Date:  2013-04       Impact factor: 0.982

8.  Transient hepatic attenuation difference (THAD) following transcatheter arterial chemoembolization for hepatic malignancy: changes on serial CT examinations.

Authors:  Sung Ho Hwang; Jeong-Sik Yu; Jin Chung; Jae-Joon Chung; Joo Hee Kim; Ki Whang Kim
Journal:  Eur Radiol       Date:  2008-03-20       Impact factor: 5.315

9.  [Incidental findings of liver, biliary system, pancreas and spleen in asymptomatic patients : Assessment and management recommendations].

Authors:  M Scharitzer; D Tamandl; A Ba-Ssalamah
Journal:  Radiologe       Date:  2017-04       Impact factor: 0.635

Review 10.  That liver lesion on MDCT in the oncology patient: is it important?

Authors:  Richard M Gore; Kiran H Thakrar; Daniel R Wenzke; Geraldine M Newmark; Uday K Mehta; Jonathan W Berlin
Journal:  Cancer Imaging       Date:  2012-09-28       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.